Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021
April 16, 2021 08:05 ET
|
Adverum Biotechnologies, Inc.
-- Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT -- REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM),...
Adverum Files Definitive Proxy Materials and Mails Letter to Stockholders Detailing Strength of Team and Acceleration Toward Commercialization of ADVM-022
April 15, 2021 08:00 ET
|
Adverum Biotechnologies, Inc.
Urges Stockholders to Vote the WHITE Proxy Card “FOR ALL” of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed Tuckson, M.D. and Tom Woiwode, Ph.D. Annual...
Adverum Announces Senior Appointments for Patient Access and Clinical Operations as ADVM-022 Advances Toward Global Phase 3 Trials
March 30, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
-- Anand Reddi appointed vice president, patient advocacy, access, and digital innovation -- -- Bill Tan, PharmD, appointed vice president, clinical operations program lead -- REDWOOD CITY,...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare...
Adverum Announces Board Slate for 2021 Annual Meeting and Reiterates Commitment to Stockholder Value Creation
March 17, 2021 17:10 ET
|
Adverum Biotechnologies, Inc.
Responds to Intent to Nominate Directors from Sonic Fund Sonic’s Attempt to Control the Board Not in the Best Interests of Adverum or the Company’s Stockholders REDWOOD CITY, Calif., March 17,...
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
March 01, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
-- BLA submission targeted in 2024 -- -- Alignment on clinical development and CMC requirements from recent interactions with FDA -- -- Two global Phase 3 trials expected to enroll 900 patients in...
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
February 22, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors
February 22, 2021 09:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum Appoints Christopher J. DeRespino as Chief Business Officer
February 18, 2021 16:00 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...
Adverum to Present Data from the OPTIC Phase 1 Trial with ADVM-022 Intravitreal Gene Therapy in Wet AMD at the Angiogenesis, Exudation, and Degeneration 2021 Virtual Meeting
February 10, 2021 16:49 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...